Search results
Results from the WOW.Com Content Network
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology , PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically.
When cancer patients with a defect in MMR in their tumors were exposed to an inhibitor of PD-1, 67–78% of patients experienced immune-related progression-free survival. In contrast, for patients without defective MMR, addition of PD-1 inhibitor generated only 11% of patients with immune-related progression-free survival.
During the trial, Sarclisa was administered by intravenous infusion at a dose of 10mg/kg once weekly for four weeks, then every other week for 28-day cycles in combination with standard doses of Pd for the duration of treatment. The primary endpoint of ICARIA-MM was progression-free survival (PFS). Key secondary endpoints included ORR and OS.
Their ability to remain multicellular throughout metastasis, may explain their superior survival and metastatic potential. [25] Research on CTC clusters and their role in metastasis continues to evolve, with the cancer exodus hypothesis offering a new perspective on how these clusters contribute to cancer progression.
"The magnitude of this breakthrough in cancer research cannot be overstated," said Dr. David Platt, CEO of Bioxytran Inc. "Our findings herald a significant shift in cancer treatment paradigms. We've developed a robust theory of cancer and metastasis, identifying Galectin-3 as a pivotal driver of disease progression.
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
Median progression free survival (PFS) and overall survival (OS) both improved by six months in the dose adjusted group. [ 25 ] One approach that can help clinicians individualize chemotherapy dosing is to measure the drug levels in blood plasma over time and adjust dose according to a formula or algorithm to achieve optimal exposure.
Progression-free survival - the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse. Survival rate – indicating the percentage of people in a study or treatment group who are alive for a given period of time after diagnosis. Survival time – the remaining duration ...